MD-CERTIS-BIOLOGICALS
11.8.2021 15:19:08 CEST | Business Wire | Press release
To meet the rising demand for biological-based crop protection products, Certis Biologicals today announced new additions to its headquarters team. Tarang Srivastava begins immediately as Head of International Business, responsible for business strategy and financial objectives in international markets and working with distribution partners, external business partners and internal teams to expand biologicals globally. Srivastava’s focus will lay in providing solutions to growers in European markets. Srivastava formally worked on Bharat Certis Insecticide Limited for parent company Mitsui & Co. and brings extensive experience in establishing global positions to the new role.
Additionally, Certis Biologicals welcomes Moto Mitani to the International Business Team. Mitani will lead the Certis teams for Asia and Africa as well as supporting Certis Biologicals’ Specialty Chemical Sales division. Mitani joins from Mitsui AgriScience where he served as Business Manager responsible for international sales.
Amanda Eade joins the Global Marketing Team as Global Portfolio Manager for Bioinsecticides and Bioherbicides, assessing market capacity for Certis’ proven portfolio of bio-based insecticide and herbicide solutions, including Bt portfolio products, Firefighter© , Requiem Prime© and Homeplate© . Eade brings extensive experience from posts with Open Book Extracts as Operations Manager, BASF as portfolio manager and Dow Agrisciences as sales representative.
“Currently, Certis Biologicals distributes bio-based solutions in more than 50 countries worldwide and we see a growing need in areas where synthetic chemistries are growing scarce and regulations are high,” says Amy O’Shea, President and CEO. “We want to ensure that every grower, no matter where they are located, has access to our portfolio and we believe these additions to our staff will be key to achieving that goal.”
The additions of Srivastava, Mitani and Eade come in the wake of Certis Biologicals’ announcement that Rob Gibson joined as Global Product Manager and Ryutaro Matsuhashi, VP of International Business, had expanded his role within the biologicals leader to focus on growth in Latin America. In that capacity, Matsuhashi has seen success in expanding the company’s portfolio in Brazil.
“We are proud to be headquartered in the U.S., but Certis Biologicals is a true global distributor of biologicals,” says O’Shea. “We are investing in the talent and expertise needed to ensure that we can be the full-line provider of biologicals to all growers and distributors.”
Currently, Certis Biologicals innovates across six technology platforms, including bacteria-based technologies, fungi-based products, virus technologies, bacteriophage technologies, biochemicals and need-seed extracts. The company distributes nearly 40 integrated biological crop protection solutions to growers in more than 50 countries. Certis’ robust research and development pipeline is planning numerous new products and formulations coming to market over the next 3-5 years.
Growers and distributors who are interested in Certis Biologicals can visit www.CertisBio.com to learn more about the company’s portfolio of bio-solutions for organic and conventional farming.
About Certis Biologicals
Certis Biologicals is the leading manufacturer, innovator, developer and marketer of proven biological solutions for use in commercial agriculture and the garden and greenhouse markets.
With biological products sold through a global distribution network and in collaboration with various technology, regulatory and sourcing companies in more than 50 countries, Certis Biologicals meets the challenges faced by today’s growers around the globe to feed a growing population while sustaining the natural resources and environments necessary for a healthy planet.
To learn more about Certis Biologicals, their portfolio of proven solutions, or their commitment to sustainability, visit www.CertisBio.com or follow the company through social media on Facebook , Twitter , LinkedIn and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005074/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom